Antibody Catalogue

Working With CRT

Testimonials

Licensing Portfolio

Small Molecules

Biological Therapeutics

Mouse & Cell Line Portfolio

CRT's Discovery Pipeline

Commercialisation Routes

Antibody Portfolio - M

Antigen	Clone
Macrophage	5/9
Maltose binding protein	R29.6
Maltose binding protein	R3.2
Maltose binding protein	TVG MBP 3
Mast cells	MCG35
MCM5	6G8A4F10
MCM5	A2.1G2.A7.C12.A11
MCM5	A2.5A12.A12.A11.A7
MCM5	A2.7A3.F12.A7
MCM5	A2.7B10.A12.B8.C12
MCM5	A2.12E7.B12.A8.D11
MCM5	A4.8D6.H10.D9
MCM5	A2.2C9.C9.C11.A12
Metapneumovirus	hMPV 33
Metapneumovirus	hMPV 57
Metapneumovirus Fusion Protein	hMPV 24
Metapneumovirus Nucleoprotein	hMPV 123
MDM2	SMP 14
MDM2 phospho-specific	2G2
Melanoma	LHM 3
Melanoma Associated Chrondroitin Sulphate Proteogycan (MACP)	LHM2
MHC Class II	BU20
MHC I (HLA-ABC)	BU8 (HJ13)
β2- microglobulin	BBM.1
MOS	R38.1
MOS	S3.1
Mouse ACF1	mACF1
MRP-14	MRP 1H9
MRP-8	MRP8 2C5/4
MRP-8	MRP8 7C12/4
MRP-8 and MRP-14	5.5
MUC1	SM3
MUC2	994/152
MUC18 (CD146)	OJ79c MUC 18
Mucin glycoprotein	C-Mu1
Mus81	MTA30 2G10/3
c-Myc	9E11
c-Myc epitope tag	9E10
Myofibroblasts	PR 2D3

For further information about antibodies from CRT or to discuss sales or licensing options, please contact us at reagents@cancertechnology.com

Please note that CRT supplies to distributors only. However, we are happy to direct researchers to the appropriate commercial party to obtain antibodies within our portfolio. Click here to view disclaimer information.